Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$441.13 USD
-5.75 (-1.29%)
Updated May 29, 2024 04:00 PM ET
After-Market: $441.08 -0.05 (-0.01%) 7:32 PM ET
3-Hold of 5 3
C Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 121 - 140 ( 326 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Beyond CF, Pipeline Advancement Continues in AATD and APOL1 Kidney Disease; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Alpha-1 KOL Offers Perspective on Current AATD Approaches and VX-814, Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
KOL Reception and Dinner on Alpha-1 Antitrypsin Deficiency (AATD)
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Strategic Collaboration Adds Targeted Protein Degradation Expertise to Developmental Arsenal; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Beyond Cystic Fibrosis: Thoughts Around AATD Therapy Development; Reit Buy and $220 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A